Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation - PubMed
3 hours ago
- #Clinical Trial
- #Atrial Fibrillation
- #Stroke Prevention
- The CHAMPION-AF trial compared left atrial appendage closure with NOAC therapy in atrial fibrillation patients suitable for anticoagulation.
- At 3 years, left atrial appendage closure was noninferior to NOACs for the composite endpoint of cardiovascular death, stroke, or systemic embolism (5.7% vs. 4.8%).
- Left atrial appendage closure was superior to NOACs in reducing non-procedure-related bleeding (10.9% vs. 19.0%).
- The findings suggest that device-based closure is a viable alternative for eligible patients, offering similar stroke prevention with lower bleeding risk.